In the last decade, pharmaceutical companies have seen rapid changes in the market environment for their new brand launches. While austerity measures in many countries are increasing local and national hurdles for market access, drug launches are becoming more numerous, smaller, and more competitive. It has never been more important for pharmaceutical companies to master the art of launching new products. YOU ONLY CAN DO IT ONCE!
The Content: The course content builds on the expertise and experience that the experts have accumulated over the last 15 years in advising and implementing major product launches in EMEA across major therapy areas: Oncology (incl. Immunotherapy), Immunology, CNS, CVS and Metabolic Disorders. It covers all concepts and evidence-based tools for effective strategic decision- making and planning in the process up to launch, with a focus on what will determine the brand’s commercial success.
The Experts: The faculty combines academic rigour with best practice within big pharma. Joeri De Haes was formerly a professor of marketing and since 2009 leads a team of pharma market strategy experts that combines in-depth industry knowledge with advanced analytics and team-mobilization skills. He has 10 years of experience in advising major pharma companies on global and European launch programmes for some of their strategic brands. By contrast, Kurt Arco was with MSD (Merck & Co) until recently, where he led several major product launches in many geographical areas and contributed to, and piloted, major marketing & sales excellence projects. Their company Trilations is a strategy consultancy agency that works closely with most of the major pharmaceutical and medical device companies in more than 40 countries worldwide (e.g. Johnson & Johnson, MSD, Roche, Pfizer, Boston Scientific, …).
^ 7 – 8 June 2018 in Brussels
^ 11 – 12 October 2018 in Zurich
^ 4 – 5 December 2018 in Brussels